Article
Knoxville, Tenn. - Provectus Pharmaceuticals has received allowance of its patent application in the European Union to cover PH-10, as well as other related agents and their use, Businesswire reports.
Knoxville, Tenn.
- Provectus Pharmceuticals has received allowance of its patent application in the European Union for PH-10, as well as other related agents and their use, according to Businesswire.
The pending patents cover topical applications for treatment of psoriasis and eczema. Currently, PH-10 is undergoing a phase 2 clinical trial in New York City for the treatment of moderate to severe psoriasis, Businesswire reports.
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.